Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease

Dong Hyuk Seo, Xiumei Che, Min Seob Kwak, Soochan Kim, Jae Hyeon Kim, Hyun Woo Ma, Da Hye Kim, Tae Il Kim, Won Ho Kim, Seung Won Kim, JaeHee Cheon

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Interleukin 33 (IL-33) that signals through the ST2 receptor has emerged as a critical modulator in several inflammatory disorders, including inflammatory bowel disease (IBD). However, the precise mechanisms by which IL-33 modulates IBD are controversial. The aim of this study was thus to clarify the role of IL-33 in IBD. The plasma levels of IL-33 were significantly decreased, but soluble ST2 levels were increased in patients with IBD compared to healthy individuals. Moreover, IL-33 restored goblet cell numbers and induced macrophage switching from the M1 to the M2 phenotype. These effects were sufficient to ameliorate colitis in dextran sodium sulfate, trinitrobenzene sulfonic acid, and peritoneal cavity cell transfer models. IL-33 facilitated goblet cell restoration via modulating macrophages toward the M2 phenotype. In addition, wound healing was significantly faster in IL-33-treated human monocyte-derived macrophages than in control cells, which could be attributed to increased polarisation into M2 macrophages. We found that patients with IBD show decreased serum levels of IL-33 compared with healthy individuals and that IL-33 can attenuate colitis and aid tissue repair in mice. The mechanism by which IL-33 exerts these effects appears to involve the stimulation of differentiation of goblet cells and M2 macrophages.

Original languageEnglish
Article number851
JournalScientific reports
Volume7
Issue number1
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Inflammatory Bowel Diseases
Macrophages
Inflammation
Goblet Cells
Colitis
Trinitrobenzenes
Phenotype
Interleukin-33
Dextran Sulfate
Sulfonic Acids
Peritoneal Cavity
Wound Healing
Cell Count
Serum

All Science Journal Classification (ASJC) codes

  • General

Cite this

Seo, Dong Hyuk ; Che, Xiumei ; Kwak, Min Seob ; Kim, Soochan ; Kim, Jae Hyeon ; Ma, Hyun Woo ; Kim, Da Hye ; Kim, Tae Il ; Kim, Won Ho ; Kim, Seung Won ; Cheon, JaeHee. / Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease. In: Scientific reports. 2017 ; Vol. 7, No. 1.
@article{0221d29cfaad4b48974f59d3d6876911,
title = "Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease",
abstract = "Interleukin 33 (IL-33) that signals through the ST2 receptor has emerged as a critical modulator in several inflammatory disorders, including inflammatory bowel disease (IBD). However, the precise mechanisms by which IL-33 modulates IBD are controversial. The aim of this study was thus to clarify the role of IL-33 in IBD. The plasma levels of IL-33 were significantly decreased, but soluble ST2 levels were increased in patients with IBD compared to healthy individuals. Moreover, IL-33 restored goblet cell numbers and induced macrophage switching from the M1 to the M2 phenotype. These effects were sufficient to ameliorate colitis in dextran sodium sulfate, trinitrobenzene sulfonic acid, and peritoneal cavity cell transfer models. IL-33 facilitated goblet cell restoration via modulating macrophages toward the M2 phenotype. In addition, wound healing was significantly faster in IL-33-treated human monocyte-derived macrophages than in control cells, which could be attributed to increased polarisation into M2 macrophages. We found that patients with IBD show decreased serum levels of IL-33 compared with healthy individuals and that IL-33 can attenuate colitis and aid tissue repair in mice. The mechanism by which IL-33 exerts these effects appears to involve the stimulation of differentiation of goblet cells and M2 macrophages.",
author = "Seo, {Dong Hyuk} and Xiumei Che and Kwak, {Min Seob} and Soochan Kim and Kim, {Jae Hyeon} and Ma, {Hyun Woo} and Kim, {Da Hye} and Kim, {Tae Il} and Kim, {Won Ho} and Kim, {Seung Won} and JaeHee Cheon",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-00840-2",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Seo, DH, Che, X, Kwak, MS, Kim, S, Kim, JH, Ma, HW, Kim, DH, Kim, TI, Kim, WH, Kim, SW & Cheon, J 2017, 'Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease', Scientific reports, vol. 7, no. 1, 851. https://doi.org/10.1038/s41598-017-00840-2

Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease. / Seo, Dong Hyuk; Che, Xiumei; Kwak, Min Seob; Kim, Soochan; Kim, Jae Hyeon; Ma, Hyun Woo; Kim, Da Hye; Kim, Tae Il; Kim, Won Ho; Kim, Seung Won; Cheon, JaeHee.

In: Scientific reports, Vol. 7, No. 1, 851, 01.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease

AU - Seo, Dong Hyuk

AU - Che, Xiumei

AU - Kwak, Min Seob

AU - Kim, Soochan

AU - Kim, Jae Hyeon

AU - Ma, Hyun Woo

AU - Kim, Da Hye

AU - Kim, Tae Il

AU - Kim, Won Ho

AU - Kim, Seung Won

AU - Cheon, JaeHee

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Interleukin 33 (IL-33) that signals through the ST2 receptor has emerged as a critical modulator in several inflammatory disorders, including inflammatory bowel disease (IBD). However, the precise mechanisms by which IL-33 modulates IBD are controversial. The aim of this study was thus to clarify the role of IL-33 in IBD. The plasma levels of IL-33 were significantly decreased, but soluble ST2 levels were increased in patients with IBD compared to healthy individuals. Moreover, IL-33 restored goblet cell numbers and induced macrophage switching from the M1 to the M2 phenotype. These effects were sufficient to ameliorate colitis in dextran sodium sulfate, trinitrobenzene sulfonic acid, and peritoneal cavity cell transfer models. IL-33 facilitated goblet cell restoration via modulating macrophages toward the M2 phenotype. In addition, wound healing was significantly faster in IL-33-treated human monocyte-derived macrophages than in control cells, which could be attributed to increased polarisation into M2 macrophages. We found that patients with IBD show decreased serum levels of IL-33 compared with healthy individuals and that IL-33 can attenuate colitis and aid tissue repair in mice. The mechanism by which IL-33 exerts these effects appears to involve the stimulation of differentiation of goblet cells and M2 macrophages.

AB - Interleukin 33 (IL-33) that signals through the ST2 receptor has emerged as a critical modulator in several inflammatory disorders, including inflammatory bowel disease (IBD). However, the precise mechanisms by which IL-33 modulates IBD are controversial. The aim of this study was thus to clarify the role of IL-33 in IBD. The plasma levels of IL-33 were significantly decreased, but soluble ST2 levels were increased in patients with IBD compared to healthy individuals. Moreover, IL-33 restored goblet cell numbers and induced macrophage switching from the M1 to the M2 phenotype. These effects were sufficient to ameliorate colitis in dextran sodium sulfate, trinitrobenzene sulfonic acid, and peritoneal cavity cell transfer models. IL-33 facilitated goblet cell restoration via modulating macrophages toward the M2 phenotype. In addition, wound healing was significantly faster in IL-33-treated human monocyte-derived macrophages than in control cells, which could be attributed to increased polarisation into M2 macrophages. We found that patients with IBD show decreased serum levels of IL-33 compared with healthy individuals and that IL-33 can attenuate colitis and aid tissue repair in mice. The mechanism by which IL-33 exerts these effects appears to involve the stimulation of differentiation of goblet cells and M2 macrophages.

UR - http://www.scopus.com/inward/record.url?scp=85018781441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018781441&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-00840-2

DO - 10.1038/s41598-017-00840-2

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 851

ER -